## **Core Concept**
The question tests understanding of oral hypoglycemic agents, specifically their mechanisms of action. Insulin secretagogues are drugs that stimulate the release of insulin from the pancreatic beta cells.

## **Why the Correct Answer is Right**
Metformin is the correct answer because it does not stimulate insulin secretion. Instead, it works by decreasing hepatic glucose production, enhancing insulin sensitivity, and facilitating glucose uptake by muscles.

## **Why Each Wrong Option is Incorrect**
* **Option A:** Sulfonylureas (e.g., glyburide) stimulate insulin release from pancreatic beta cells, making them insulin secretagogues.
* **Option B:** Meglitinides (e.g., repaglinide) also stimulate insulin release from the pancreas, classifying them as insulin secretagogues.
* **Option D:** Sulfonylurea-like drugs (e.g., gliclazide) have a similar mechanism to sulfonylureas, acting as insulin secretagogues.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Metformin is the first-line treatment for type 2 diabetes** and works by **increasing insulin sensitivity** and **decreasing hepatic gluconeogenesis**, not by stimulating insulin secretion.

## **Correct Answer:** . Metformin